STN: BLA 125700
Proper Name: nadofaragene firadenovec-vncg
Tradename: ADSTILADRIN
Manufacturer: Ferring Pharmaceuticals A/S
Indication:
- ADSTILADRIN is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Product Information
Supporting Documents
-
Content current as of:
10/10/2025



